Patents by Inventor Philip Wilson

Philip Wilson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9388187
    Abstract: A compound with the formula I: wherein: R2 is of formula II: where A is a C5-7 aryl group, X is selected from the group comprising: NHNH2, CONHNH2, formula III, formula IV, and either: (i) Q1 is a single bond, and Q2 is selected from a single bond and —Z—(CH2)n—, where Z is selected from a single bond, O, S and NH and n is from 1 to 3; or (ii) Q1 is —CH?CH—, and Q2 is a single bond; R12 is a C5-10 aryl group, optionally substituted by one or more substituents selected from the group comprising: halo, nitro, cyano, ether, C1-7 alkyl, C3-7 heterocyclyl and bis-oxy-C1-3 alkylene; R6 and R9 are independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR?, nitro, Me3Sn and halo; where R and R? are independently selected from optionally substituted C1-12 alkyl, C3-20 heterocyclyl and C5-20 aryl groups; R7 is selected from H, R, OH, OR, SH, SR, NH2, NHR, NHRR?, nitro, Me3Sn and halo; either: (a) R10 is H, and R11 is OH, ORA, where RA is C1-4 alkyl; (b) R10 and R11 form a nitrogen-carbon double bond between the n
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: July 12, 2016
    Assignee: MEDIMMUNE LIMITED
    Inventor: Philip Wilson Howard
  • Patent number: 9387258
    Abstract: A compound, or a pharmaceutically acceptable salt or solvate thereof, or conjugates thereof, selected from the group consisting of formula wherein: (a) R10 is H, and R11 is OH, ORA, where RA is saturated C1-4 alkyl; (b) R10 and R11 form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or (c) R10 is H and R11 is S02M, where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation, or both M together are a divalent pharmaceutically acceptable cation.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: July 12, 2016
    Assignees: SEATTLE GENETICS, INC., MEDIMMUNE LIMITED
    Inventors: Scott Jeffrey, Patrick Burke, Philip Wilson Howard
  • Patent number: 9387259
    Abstract: This invention relates to pyrrolobenzodiazepines (PBDs), in particular pyrrolobenzodiazepine dimers having a C2-C3 double bond and an aryl group at the C2 position in each monomer unit, and their inclusion in targeted conjugates. The differing substituent groups may offer advantages in the preparation and use of the compounds, particularly in their biological properties and the synthesis of conjugates, and the biological properties of these conjugates.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: July 12, 2016
    Assignees: SEATTLE GENETICS, INC., MEDIMMUNE LIMITED
    Inventors: Scott Jeffrey, Patrick Burke, Philip Wilson Howard
  • Patent number: 9376440
    Abstract: Novel pyrrolobenzodiazepines (PBDs) having a (1-methyl-1H-pyrrol-3-yl)phenyl based amino acid residue and use thereof as antiproliferative agents are disclosed herein.
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: June 28, 2016
    Assignee: MEDIMMUNE LIMITED
    Inventors: Philip Wilson Howard, David Edwin Thurston, Khondaker Mirazur Rahman
  • Publication number: 20160144052
    Abstract: A conjugate of formula (A):
    Type: Application
    Filed: March 13, 2014
    Publication date: May 26, 2016
    Inventors: Philip Wilson Howard, John A. Flygare, Thomas Pillow, Binqing Wei
  • Publication number: 20160129013
    Abstract: Provided are Conjugate comprising PBDs conjugated to a targeting agent and methods of using such PBDs.
    Type: Application
    Filed: January 14, 2016
    Publication date: May 12, 2016
    Inventors: Philip Wilson HOWARD, Scott JEFFREY, Patrick BURKE, Peter SENTER
  • Patent number: 9321774
    Abstract: A compound of formula (I) or a salt or solvate thereof, wherein the dotted double bond indicates the presence of a single or double bond between C2 and C3; R2 is selected from —H, —OH, ?O, ?CH2, —CN, —R, OR, halo, dihalo, ?CHR, ?CHRR?, —O—SO2—R, CO2R and COR; R7 is selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR?, nitro, Me3Sn and halo; where R and R? are independently selected from optionally substituted C1-7 alkyl, C3-20 heterocyclyl and C5-20 aryl groups; R10 and R11 either together form a double bond, or are selected from H and QRQ respectively, where Q is selected from O, S and NH and RQ is H or C1-7 alkyl or H and SOxM, where x is 2 or 3, and M is a monovalent pharmaceutically acceptable cation; A is selected from (A1), (A2), (A3), (A4) or (A5) where X1 and Y1 are selected from: CH and NH; CH and NMe; N and NMe; CH and S; N and S; N and O; and CH and O, respectively; X2 and Y2 are selected from: CH and NH; CH and NMe; N and NMe; CH and S; N and S; N and O; and CH and O, respectively; Z1 is selected fr
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: April 26, 2016
    Assignee: MEDIMMUNE LIMITED
    Inventors: Philip Wilson Howard, David Edwin Thurston, Khondaker Mirazur Rahman, Peter William Taylor
  • Publication number: 20160106861
    Abstract: The present invention relates to an antibody-drug conjugate capable of binding to the protein Axl. From one aspect, the invention relates to an antibody-drug conjugate comprising an antibody capable of binding to Axl, said antibody being conjugated to at least one drug which is a pyrrolobenzodiazepme dimer (PBD dimer) drug. The invention also comprises method of treatment and the use of said antibody-drug conjugate for the treatment of cancer.
    Type: Application
    Filed: April 28, 2014
    Publication date: April 21, 2016
    Applicants: SPIROGEN SARL, PIERRE FABRE MEDICAMENT
    Inventors: Charlotte BEAU-LARVOR, Liliane GOETSCH, Philip Wilson HOWARD
  • Publication number: 20160059795
    Abstract: A display screen surface-mounting structure (100) comprising a display screen connector (111, 113), a surface connector (115, 117) for connecting the structure to a surface in use, and further comprising a rotational movement mechanism for axial rotation of an attached display screen (400) in use, wherein the rotational movement mechanism comprises an electric drive (109) and an manual rotational adjustment mechanism, and wherein the rotational movement mechanism comprises first and second dampers (105, 109), arranged to be connected either side of a connected display screen (400), in use.
    Type: Application
    Filed: April 15, 2014
    Publication date: March 3, 2016
    Applicant: BENTLEY MOTORS LIMITED
    Inventors: David Alan Rook, Philip Wilson
  • Patent number: 9266894
    Abstract: A compound with the formula I wherein: R2 is of formula II where Q is selected from OH, SH and NRN, and RN is selected from H, methyl and ethyl, as well as drug-linkers and drug-conjugates made from this compound.
    Type: Grant
    Filed: September 20, 2012
    Date of Patent: February 23, 2016
    Assignee: MEDIMMUNE LIMITED
    Inventor: Philip Wilson Howard
  • Publication number: 20160031887
    Abstract: A conjugate of formula (A): and salts and solvates thereof.
    Type: Application
    Filed: March 13, 2014
    Publication date: February 4, 2016
    Inventor: Philip Wilson HOWARD
  • Patent number: 9242013
    Abstract: Provided are Conjugate comprising PBDs conjugated to a targeting agent and methods of using such PBDs.
    Type: Grant
    Filed: April 15, 2011
    Date of Patent: January 26, 2016
    Assignees: SEATTLE GENETICS INC., MEDIMMUNE LIMITED
    Inventors: Philip Wilson Howard, Scott Jeffrey, Patrick Burke, Peter Senter
  • Publication number: 20160015828
    Abstract: Provided are novel antibody drug conjugates (ADCs), and methods of using such ADCs to treat proliferative disorders.
    Type: Application
    Filed: February 21, 2014
    Publication date: January 21, 2016
    Applicants: Spirogen Sàrl, Stemcentrx, Inc.
    Inventors: Michael TORGOV, Philip Wilson HOWARD
  • Publication number: 20150344482
    Abstract: A compound with the formula I: and salts and solvates thereof.
    Type: Application
    Filed: December 20, 2013
    Publication date: December 3, 2015
    Inventor: Philip Wilson HOWARD
  • Publication number: 20150315196
    Abstract: A compound of formula I: or a pharmaceutically acceptable salt or solvate thereof.
    Type: Application
    Filed: December 20, 2013
    Publication date: November 5, 2015
    Inventor: Philip Wilson HOWARD
  • Publication number: 20150297746
    Abstract: Conjugates of an antibody that binds to CD25 with PBD dimers.
    Type: Application
    Filed: October 11, 2013
    Publication date: October 22, 2015
    Inventors: Patricius Hendrikus Cornelis VAN BERKEL, Philip Wilson HOWARD
  • Publication number: 20150283258
    Abstract: Conjugates of an antibody that binds to PSMA with PBD dimers.
    Type: Application
    Filed: October 11, 2013
    Publication date: October 8, 2015
    Inventors: Patricius Hendrikus Cornelis Van Berkel, Philip Wilson Howard
  • Publication number: 20150283263
    Abstract: Conjugates of an antibody that binds to CD25 with PBD dimers.
    Type: Application
    Filed: October 11, 2013
    Publication date: October 8, 2015
    Inventors: Patricius Hendrikus Cornelis Van Berkel, Philip Wilson Howard
  • Publication number: 20150283262
    Abstract: Conjugates of an antibody that binds to CD19 with PBD dimers.
    Type: Application
    Filed: October 11, 2013
    Publication date: October 8, 2015
    Inventors: Patricius Hendrikus Cornelis Van Berkel, Philip Wilson Howard
  • Publication number: 20150273077
    Abstract: Conjugates of an antibody that binds to HER2 with PBD dimers.
    Type: Application
    Filed: October 11, 2013
    Publication date: October 1, 2015
    Inventors: Patricius Hendrikus Cornelis Van Berkel, Philip Wilson Howard